A study suggests that strains of ruminococcus (blautia) gnavus (RG) seen in the gut microbiome of patients in active lupus nephritis might be drivers of disease flares and highlight the possible pathogenic qualities of specific strains.
Blooms of the gut bacterium Ruminococcus (blautia) gnavus (RG) may be a prevalent motivator of clinical flares of often remitting-relapsing lupus disease, according to a study published in Annals of the Rheumatic Diseases. The findings emphasize the possible pathogenic properties of particular strains of gut bacteria in patients with active lupus nephritis (LN).
Study authors explored the relationships between microbiota community resilience and disease activity in what was the first longitudinal analysis of lupus gut microbiota communities to the authors' knowledge. The study was conducted because while genetic susceptibility for systemic lupus erythematosus (SLE) has been thoroughly investigated, the triggers for clinical disease flares have not been well-defined.
“Lupus nephritis (LN) is a serious illness, yet despite improvements in therapeutic interventions, many patients progress to renal failure [and] the causes of lupus flares are unknown,” explained the study authors.
First, they examined 2-6 fecal samples from 16 female patients, with 44 samples collected over 24-291 weeks. For comparison, 72 sequential samples from 22 healthy adult female control volunteers were evaluated. To review the diversity in the bacterial communities, fecal DNA was used to generate 16S rRNA gene-amplicon libraries.
Next, an observational study was conducted in which taxononomic analyses, including a multivariate analysis of ß-diversity, evaluated changes in fecal communities from patients and healthy controls over time. Strains were separated from gut blooms and genomes and associated glycans were analyzed.
Regarding the results, “Multivariate analyses documented that, unlike healthy controls, significant temporal community-wide ecological microbiota instability was common in SLE patients, and transient intestinal growth spikes of several pathogenic species were documented,” said the study authors.
Only RG, which is an anaerobic commensal, expanded at times of high disease activity, and RG expansions were seen in almost 50% of patients during LN disease flares.
Whole-genome sequence analysis of RG strains separated during these flares showed 34 genes thought to aid adaptation and expansion within a host with an inflammatory condition. The most specific feature of strains discovered during lupus flares was the expression of a novel type of cell membrane-associated lipoglycan, the expression of which is associated with high-level serum IgG2 antibodies that arose concurrently with RG blooms and lupus flares in the study.
The study authors notably indicated that instability, defined by the level of community variance over time, was not related to the number of samples from a donor, the timespan of sampling, or the disease activity features. Nor was the instability correlated with maximum systemic lupus erythematosus disease activity index (SLEDAI) disease score at sampling, or span from lowest to highest SLEDAI score in the person. Impaired gut community stability has not been considered before. Also, temporal microbiota instability did not seem to correlate with the ingested medication, that suggests that community instability could be an intrinsic feature to LN.
Even though the study authors’ knowledge of the diversity among RG strains is still relatively limited, their analysis of 9 RG strains from patients with inflammatory bowel disease found no detectable LG, although these studies are not exhaustive, they noted.
“Our studies document key structural features of the RG LG that display remarkable conservation between different LN-derived strains (figure 5),” continued the authors.
Additionally, the LG in this study that was purified and characterized, so far in 3 RG strains, was found to have a unique structure with multiple distinctive features that merit more study and clarification.
Disease flares might be influenced by ecological shifts in a microbiota community that is inclusive of a range of RG strains that differ based on genomic gene sets and expressed glycan properties. Preliminary studies have observed that as far as LG producing RG strains, there is a specific blood transcriptomic profile seen in patients with SLE with RG blooms parallel to disease flares, wich could be relevant to the pathogenesis of LN.
One limitation of this study is that it included a small cohort of only 9 patients with SLE and 22 healthy subjects were studied over time, and samples were obtained during routine clinical care. So, the true occurrence of disease flares with temporally linked RG blooms could have been underestimated, and authors were unable to evaluate the duration of bloom persistence.
“In conclusion, an individual RG strain can express different specific types of bacterial glycans, which include the novel LG expressed by lupus strains,” wrote the authors.
Reference
Azzouz DF, Chen Z, Izmirly PM, et al. Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares. Ann Rheum Dis. Published Online June 26, 2023. doi: 10.1136/ard-2023-223929
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More
Disease-Modifying Antirheumatic Drugs Linked to Decreased Risk for Autoimmune Thyroid Disease
November 28th 2023A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis.
Read More
Network Meta-Analysis Validates the Use of Methotrexate in RA Compared With Other Treatments
November 24th 2023A network meta-analysis confirmed the efficacy of methotrexate for patients with rheumatoid arthritis (RA) and validated it as the primary reference conventional synthetic disease-modifying antirheumatic drug for treatment in this population.
Read More
Telitacicept Efficacious, Safe in Treating Patients With RA, Inadequate MTX Response
November 18th 2023In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in American College of Rheumatology-20 (ACR20), ACR50, and Disease Activity Score in 28 joints with Erythrocyte Sedimentation Rate responses.
Read More
Rituximab Demonstrates Potential Efficacy in Treatment of Special Forms of RA
November 8th 2023A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with improved outcomes.
Read More